Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in <i>EGFR</i> -Mutant Lung Cancer
Adam J. Schoenfeld(Memorial Sloan Kettering Cancer Center), Helena A. Yu(Memorial Sloan Kettering Cancer Center), Michael Offin(Memorial Sloan Kettering Cancer Center), Joseph M. Chan(Columbia University Irving Medical Center), Yahya Daneshbod(Memorial Sloan Kettering Cancer Center), Romel Somwar(Memorial Sloan Kettering Cancer Center), Mark G. Kris(Cornell University), Monika A. Davare(Oregon Health & Science University), Marc Ladanyi(Memorial Sloan Kettering Cancer Center), Maria E. Arcila(Memorial Sloan Kettering Cancer Center), Jason C. Chang(Memorial Sloan Kettering Cancer Center), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Ujwal Shinde(Oregon Health & Science University), Dana Pe’er(Parker Institute for Cancer Immunotherapy), Natasha Rekhtman(Memorial Sloan Kettering Cancer Center), Hiroki Sato(Tokyo Medical University), Paul K. Paik(Memorial Sloan Kettering Cancer Center), Daisuke Kubota(Memorial Sloan Kettering Cancer Center), Hira Rizvi(Memorial Sloan Kettering Cancer Center)
Cited by 381
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k